Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Tepotinib |
Synonyms | |
Therapy Description |
Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tepotinib | Tepmetko | EMD1214063|EMD-1214063|EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J | MET Inhibitor 58 | Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01014936 | Phase I | Tepotinib | First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT02864992 | Phase II | Tepotinib | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 8 |
NCT04739358 | Phase Ib/II | Tepotinib | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | Terminated | USA | 0 |
NCT03940703 | Phase II | Osimertinib + Tepotinib Tepotinib | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 11 |
NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Recruiting | USA | 0 |